All In Biotech

Drug Trial Radar · NCT02971423

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

A Phase I, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jun 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Oct 2016

Primary completion

Jun 1, 2017

Study completion Jun 1, 2017

Sponsor

Lead sponsor
Entasis TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This research project is being conducted to look at the safety, tolerability, and pharmacokinetics (PK; how the human body processes a substance) of ETX2514 when given to healthy volunteers intravenously as a single dose, and when given as multiple intravenous doses for up to 8 consecutive days. As it is anticipated that ETX2514 could be used as a treatment for Acinetobacter baumannii (a type of bacteria) infections, this project will also look at whether ETX2514 will interact with the current treatments for these infections when they are administered at the same time.

Conditions

  • Acinetobacter Baumannii Infection

Interventions

  • ETX2514Drug

  • PlaceboDrug

    matching placebo infusion

  • SulbactamDrug

  • Imipenem/CilastatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with any non-serious and any serious adverse eventTime frame: up to 14 days after the last infusion of study drug (Study Day 182)
  2. Number of participants with an adverse event of the indicated causality and severityTime frame: up to 14 days after the last infusion of study drug (Study Day 182)
  3. Number of participants with abnormal, clinically significant hematology and clinical chemistry laboratory values at the indicated time points in Part ATime frame: Baseline (Day -1); Days 3, 5, 7, and 15 (Follow-up)
  4. Number of participants with abnormal, clinically significant hematology and clinical chemistry laboratory values at the indicated time points in Part BTime frame: Baseline (Day -1; Study Day [SD] 37); Days 2, 3, 5, 7, and 10 (SDs 39, 40, 42, 44, and 47, respectively); Day 22 (SD 59; Follow-up)
  5. Number of participants with abnormal, clinically significant hematology and clinical chemistry laboratory values at the indicated time points in Part CTime frame: Cohort 13: Baseline (Day -1; Study Day [SD] 80); Days 3, 4, and 7 (SDs 83, 84, and 87, respectively); Day 19 (SD 99; Follow-up). Cohort 14: Baseline; Days 3, 4, 7, and 10 (SDs 83, 84, 87, and 90, respectively); Day 22 (SD 102; Follow-up)
  6. Number of participants with abnormal, clinically significant hematology and clinical chemistry laboratory values at the indicated time points in Part DTime frame: Baseline (Day -1; SD 122); Days 2, 3, 5, 7, 10, 11, and 13 (SDs 124, 125, 127, 129, 132, and 133, respectively); Day 25 (SD 147; Follow-up)
  7. Change from Baseline in vital signs at the indicated time points in Part ATime frame: Baseline (Day -1); Days 1-3; Day 5; Day 7; Day 15 (Follow-up)
  8. Change from Baseline in vital signs at the indicated time points in Part BTime frame: Baseline (Day -1; SD 37); Days 1-10 (SDs 38-47, respectively); Day 22 (SD 59; Follow-up)
  9. Change from Baseline in vital signs at the indicated time points in Cohort 13 of Part CTime frame: Baseline (Day -1; SD 80); Days 1-7 (SDs 81-87, respectively); Day 19 (SD 99; Follow-up)
  10. Change from Baseline in vital signs at the indicated time points in Cohort 14 of Part CTime frame: Baseline (Day -1; SD 80); Days 1-10 (SDs 81-90, respectively); Day 22 (SD 102; Follow-up)
  11. Change from Baseline in vital signs at the indicated time points in Part DTime frame: Baseline (SD 122); Days 1-13 (SDs 123-135, respectively); Day 25 (SD 147; Follow-up)
  12. Change from Baseline in electrocardiogram parameters at the indicated time points in Parts A and BTime frame: Part A: Baseline (Day -1); Days 1 and 3; Follow-up visit (Day 15). Part B: Baseline (Day -1; SD 37); Days 1, 3, 5, 7, 10, and 22 (SDs 38, 40, 42, 44, 47, and 59, respectively)
  13. Change from Baseline in electrocardiogram parameters at the indicated time points in Cohort 13 in Part CTime frame: Baseline (Day -1; SD 80); Days 1, 3, 5, and 7 (SDs 81, 83, 85, and 87, respectively); Day 19 (SD 99; Follow-up)
  14. Change from Baseline in electrocardiogram parameters at the indicated time points in Cohort 14 in Part CTime frame: Baseline (Day -1; SD 80); Days 1, 3, 5, 8, and 10 (SDs 81, 83, 85, 88, and 90, respectively); Day 22 (SD 102; Follow-up)
  15. Change from Baseline in electrocardiogram parameters at the indicated time points in Part DTime frame: Baseline (SD 122); Days 1, 3, 5, 7, 9, and 11 (SDs 123, 125, 127, 129, 131, and 133, respectively); Day 13 (SD 135); Day 25 (SD 147; Follow-up)
  16. Number of participants with an infusion site reactionTime frame: up to 14 days after the last infusion of study drug (SD 182)
  17. Mean peak plasma concentration (Cmax) and plasma concentration at time t (Ct) in blood at the indicated time points in Cohorts 1-3 and 5-8 in Part ATime frame: Days 1-3
  18. Mean Cmax and Ct in blood at the indicated time points in Cohort 4 in Part ATime frame: Days 1-3
  19. Mean Cmax and Ct in blood at the indicated time points in Part BTime frame: Days 1, 2, 4, 8, 9, and 10 (SDs 38, 39, 41, 45, 46, and 47, respectively)
  20. Mean Cmax and Ct in blood at the indicated time points in Cohort 13 in Part CTime frame: Days 1-7 (SDs 81-87, respectively)
  21. Mean Cmax and Ct in blood at the indicated time points in Cohort 14 in Part CTime frame: Days 1-10 (SDs 81-90, respectively)
  22. Mean Cmax and Ct in blood at the indicated time points in Part DTime frame: Days 1, 2, 4, 11, 12, and 13 (SDs 124, 125, 127, 134, 135, and 136, respectively)
  23. Mean time to peak plasma concentration (Tmax) in blood at the indicated time points in Cohorts 1-3 and 5-8 in Part ATime frame: Days 1-3
  24. Mean Tmax in blood at the indicated time points in Cohort 4 in Part ATime frame: Days 1-3
  25. Mean Tmax in blood at the indicated time points in Part BTime frame: Days 1, 2, 4, 8, 9, and 10 (SDs 38, 39, 41, 45, 46, and 47, respectively)
  26. Mean Tmax in blood at the indicated time points in Cohort 13 in Part CTime frame: Days 1-7 (SDs 81-87, respectively)
  27. Mean Tmax in blood at the indicated time points in Cohort 14 in Part CTime frame: Days 1-10 (SDs 81-90, respectively)
  28. Mean Tmax in blood at the indicated time points in Part DTime frame: Days 1, 2, 4, 11, 12, and 13 (SDs 124, 125, 127, 134, 135, and 136, respectively)
  29. Mean AUC from time 0 to 24 hours (AUC0-24), AUC from time 0 to the last time point evaluated (AUC0-t), and AUC from time 0 and extrapolated to infinity (AUC0-∞) in blood at the indicated time points in Cohorts 1-3 in Part ATime frame: Days 1-3
  30. Mean AUC0-24, AUC0-t, and AUC0-∞ in blood at the indicated time points in Cohort 4 in Part ATime frame: Days 1-3
  31. Mean AUC0-24, AUC0-t, and AUC0-∞ in blood at the indicated time points in Part BTime frame: Days 1, 2, 4, 8, 9, and 10 (SDs 38, 39, 41, 45, 46, and 47, respectively)
  32. Mean AUC0-24, AUC0-t, and AUC0-∞ in blood at the indicated time points in Cohort 13 in Part CTime frame: Days 1-7 (SDs 81-87, respectively)
  33. Mean AUC0-24, AUC0-t, and AUC0-∞ in blood at the indicated time points in Cohort 14 in Part CTime frame: Days 1-10 (SDs 81-90, respectively)
  34. Mean AUC0-24, AUC0-t, and AUC0-∞ in blood at the indicated time points in Part DTime frame: Days 1, 2, 4, 11, 12, and 13 (SDs 124, 125, 127, 134, 135, and 136, respectively)
  35. Mean elimination rate constant (Kel) in blood at the indicated time points in Cohorts 1-3 and 5-8 in Part ATime frame: Days 1-3
  36. Mean Kel in blood at the indicated time points in Cohort 4 in Part ATime frame: Days 1-3
  37. Mean Kel in blood at the indicated time points in Part BTime frame: Days 1, 2, 4, 8, 9, and 10 (SDs 38, 39, 41, 45, 46, and 47, respectively)
  38. Mean Kel in blood at the indicated time points in Cohort 13 in Part CTime frame: Days 1-7 (SDs 81-87, respectively)
  39. Mean Kel in blood at the indicated time points in Cohort 14 in Part CTime frame: Days 1-10 (SDs 81-90, respectively)
  40. Mean Kel in blood at the indicated time points in Part DTime frame: Days 1, 2, 4, 11, 12, and 13 (SDs 124, 125, 127, 134, 135, and 136, respectively)
  41. Mean elimination half-life (t1/2) in blood at the indicated time points in Cohorts 1-3 and 5-8 in Part ATime frame: Days 1-3
  42. Mean t1/2 in blood at the indicated time points in Cohort 4 in Part ATime frame: Days 1-3
  43. Mean t1/2 in blood at the indicated time points in Part BTime frame: Days 1, 2, 4, 8, 9, and 10 (SDs 38, 39, 41, 45, 46, and 47, respectively)
  44. Mean t1/2 in blood at the indicated time points in Cohort 13 in Part CTime frame: Days 1-7 (SDs 81-87, respectively)
  45. Mean t1/2 in blood at the indicated time points in Cohort 14 in Part CTime frame: Days 1-10 (SDs 81-90, respectively)
  46. Mean t1/2 in blood at the indicated time points in Part DTime frame: Days 1, 2, 4, 11, 12, and 13 (SDs 124, 125, 127, 134, 135, and 136, respectively)
  47. Mean clearance in blood at the indicated time points in Cohorts 1-3 and 5-8 in Part ATime frame: Days 1-3
  48. Mean clearance in blood at the indicated time points in Cohort 4 in Part ATime frame: Days 1-3
  49. Mean clearance in urine at the indicated time points in Part ATime frame: Baseline (Day -1); Days 1-3
  50. Mean clearance in blood at the indicated time points in Part BTime frame: Days 1, 2, 4, 8, 9, and 10 (SDs 38, 39, 41, 45, 46, and 47, respectively)
  51. Mean clearance in urine at the indicated time points in Part BTime frame: Baseline (Day -1; SD 37); Days 1-3 and 7-10 (SDs 38-40 and 44-47, respectively)
  52. Mean clearance in blood at the indicated time points in Cohort 13 in Part CTime frame: Days 1-7 (SDs 81-87, respectively)
  53. Mean clearance in urine at the indicated time points in Cohort 13 in Part CTime frame: Baseline (Day -1; SD 80); Days 1-7 (SDs 81-87, respectively)
  54. Mean clearance in blood at the indicated time points in Cohort 14 in Part CTime frame: Days 1-10 (SDs 81-90, respectively)
  55. Mean clearance in urine at the indicated time points in Cohort 14 in Part CTime frame: Baseline (Day -1; SD 80); Days 1-10 (SDs 81-90, respectively)
  56. Mean clearance in blood at the indicated time points in Part DTime frame: Days 1, 2, 4, 11, 12, and 13 (SDs 124, 125, 127, 134, 135, and 136, respectively)
  57. Mean clearance in urine at the indicated time points in Part DTime frame: Baseline (Day -1; SD 123); Days 1-3 (SDs 124-126, respectively); Days 10-13 (SDs 133-136, respectively)
  58. Mean volume of distribution (VzVdss) in blood at the indicated time points in Cohorts 1-3 and 5-8 in Part ATime frame: Days 1-3
  59. Mean VzVdss in blood at the indicated time points in Cohort 4 in Part ATime frame: Days 1-3
  60. Mean VzVdss in blood at the indicated time points in Part BTime frame: Days 1, 2, 4, 8, 9, and 10 (SDs 38, 39, 41, 45, 46, and 47, respectively)
  61. Mean VzVdss in blood at the indicated time points in Cohort 13 in Part CTime frame: Days 1-7 (SDs 81-87, respectively)
  62. Mean VzVdss in blood at the indicated time points in Cohort 14 in Part CTime frame: Days 1-10 (SDs 81-90, respectively)
  63. Mean VzVdss in blood at the indicated time points in Part DTime frame: Days 1, 2, 4, 11, 12, and 13 (SDs 124, 125, 127, 134, 135, and 136, respectively)
  64. Mean cumulative excretion of unchanged drug in urine (Ae) at the indicated time points in Part ATime frame: Baseline (Day -1); Days 1-3
  65. Mean Ae at the indicated time points in Part BTime frame: Baseline (Day -1; SD 37); Days 1-3 and 7-10 (SDs 38-40 and 44-47, respectively)
  66. Mean Ae at the indicated time points in Cohort 13 in Part CTime frame: Baseline (Day -1; SD 80); Days 1-7 (SDs 81-87, respectively)
  67. Mean Ae at the indicated time points in Cohort 14 in Part CTime frame: Baseline (Day -1; SD 80); Days 1-10 (SDs 81-90, respectively)
  68. Mean Ae at the indicated time points in Part DTime frame: Baseline (Day -1; SD 123); Days 1-3 (SDs 124-126, respectively); Days 10-13 (SDs 133-136, respectively)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.